# Managing Post-Chemotherapy Refractory Diarrhea & Colitis
> Exploration of clinical challenges in refractory diarrhea post-chemotherapy, covering C. difficile, pembrolizumab-induced colitis (irAE), and CMV colitis.

Tags: oncology, chemotherapy-side-effects, immunotherapy-toxicities, c-difficile, clinical-case-study, pembrolizumab, medical-education
## Navigating Refractory Diarrhea Post-Chemotherapy
*   **Topic**: Diagnostic dilemma involving C. difficile, Pembrolizumab-Induced Colitis (irAE), and opportunistic infections.
*   **Framework**: Based on UKONS, CCO, and BC Cancer standards.

## Clinical Presentation
*   **Patient**: Middle-aged female with breast cancer.
*   **History**: Day +10 post-chemo (Pembrolizumab exposure).
*   **Symptoms**: 18-22 episodes of non-bloody diarrhea per day, nausea, abdominal pain, and tachycardia (Fast AF).

## Investigations & Grading
*   **Laboratory Findings**: CRP >400 mg/L, AKI Stage 2, hypokalemia (Low K+), and hypomagnesemia (Low Mg2+).
*   **Toxicity Grading**: Grade 3 Colitis (CTCAE v5.0).
*   **Response**: AKI and AF resolved post-resuscitation; CRP began trending down.

## Diagnostic Gap: C. Difficile
*   **Findings**: C. diff PCR positive, but Toxin negative. 
*   **Observation**: Flexible sigmoidoscopy confirmed Pseudomembranous Colitis. Visual evidence supersedes negative toxin assays per BC Cancer/CCO guidelines.
*   **Treatment**: High-dose Oral Vancomycin and IV Metronidazole.

## Differential Diagnoses
*   **Refractory C. diff**: Persistent symptoms after 10+ days; potential 'toxin dilution' due to high output.
*   **Pembrolizumab-Induced Colitis**: T-cell mediated attack; 'Double-Hit' hypothesis suggests previous chemotherapy mucosal injury allowed T-cell infiltration.
*   **CMV Colitis**: Potential opportunistic reactivation. Rule-out required before starting high-dose steroids.

## Integrated Management Algorithm
1.  **Rule Out CMV**: Confirm negative blood PCR.
2.  **Restore Microbiome**: Prioritize FMT (Fecal Microbiota Transplant) for refractory C. diff.
3.  **Transition to Immunosuppression**: Initiate IV Methylprednisolone 1-2 mg/kg if immune-mediated; escalate to Infliximab or Vedolizumab if refractory >48h.

## Nursing & Supportive Care
*   **Triage**: UKONS 24-Hour Triage (Red/Amber category).
*   **Electrolyte Monitoring**: Strict tracking of K+ and Mg2+ to prevent AF recurrence.
*   **Skin Integrity**: Proactive perianal care due to frequency of stools.
---
This presentation was created with [Bobr AI](https://bobr.ai) — an AI presentation generator.